Asian Pacific Journal of Cancer Prevention

  • 제16권17호
  • /
  • Pages.7859-7863
  • /
  • 2015
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Comparison of Single Agent Gemcitabine and Docetaxel in Second-Line Therapy for Advanced Stage Non-Small Cell Lung Cancer in a University Hospital in Turkey

  • Yildirim, Fatma (Pulmonary Medicine, Faculty of Medicine, Gazi University) ;
  • Baha, Ayse (Osmaniye State Hospital, Clinic of Chest Diseases) ;
  • Yurdakul, Ahmet Selim (Pulmonary Medicine, Faculty of Medicine, Gazi University) ;
  • Ozturk, Can (Pulmonary Medicine, Faculty of Medicine, Gazi University)
  • 발행 : 2015.12.03
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: To compare the efficacy and toxicity of gemcitabine versus docetaxel in a second-line setting of nonsmall cell lung cancer (NSCLC) patients previously treated with platin-based combination chemotherapy. Materials and Methods: We retrospectively evaluated the medical records of 57 patients treated with single agent gemcitabine or docetaxel in second-line setting of advanced NSCLC who received one prior platinum-based therapy. Results: The mean age was $56.7{\pm}8.39$ years with 55 (96.5%) males and two (3.5%) females. Forty of them received docetaxel and 17 gemcitabine. The mean number of chemotherapy cycles was $6.8{\pm}4.0$ in the gemcitabine group, while it was $4.6{\pm}3.0$ in the docetaxel group. Overall response rates were 8% and 12% (P=0.02) for gemcitabine and docetaxel, respectively. The median survival time was 22 versus 21 months for gemcitabine and docetaxel, respectively. The median times to progression were 8 and 5 months. There was no difference between the two groups in terms of incidence of adverse affects (40% vs 47.1%). All of the hematological side effects were grade 1/2. No major toxicity was encountered necessitating stopping the drug for either group. Conclusions: Treatment with gemcitabine demonstrated clinically equivalent efficacy with a significantly improved safety profile compared with those receiving docetaxel in the second-line setting for advanced NSCLC in this study. Based on these results, treatment with gemcitabine should be considered a standard treatment option for second-line NSCLC.

키워드

참고문헌

  1. Burris H, Eckhardt J, Fields S, et al (1993). Phase II trial of Taxotere with non-small cell lung cancer. Proc Am Soc Clin Oncol, 12, 335.
  2. Cho KH Song YB, Choi IS, et al (2006). A phase II study of single-agent gemcitabine as a second-line treatment in advanced non-small cell lung cancer. Jpn J Clin Oncol, 36, 50-4. https://doi.org/10.1093/jjco/hyi213
  3. Cobo M, Gutierrez V, Alcaide J, et al (2007). A phase II study of days 1 and 8 combination of docetaxel plus gemcitabine for the second-line treatment of patients with advanced nonsmall- cell lung cancer and good performance status. Lung Cancer, 56, 255-62. https://doi.org/10.1016/j.lungcan.2006.12.013
  4. Coskun U, Kaya AO, Buyukberber S, et al (2008). Single agent gemcitabine in the second-line treatment of advanced nonsmall cell lung cancer after treatment with taxane + platinum regimens. Med Oncol, 25, 133-6. https://doi.org/10.1007/s12032-007-9005-3
  5. Crino L, Mosconi AM, Scagliotti GV, et al (1999). Gemcitabine as second-line treatment for advanced non-small-cell lung cancer, A phase II trial. J Clin Oncol, 17, 2081-5. https://doi.org/10.1200/JCO.1999.17.7.2081
  6. Fossella FV, De Vore R, Kerr RN, et al (2000). Randomized Phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol, 18, 2354-62. https://doi.org/10.1200/JCO.2000.18.12.2354
  7. Fossella FV, Lee JS, Shin DM, et al (1995). Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol, 13, 645-51. https://doi.org/10.1200/JCO.1995.13.3.645
  8. Gandara DR, Vokes E, Green M, et al (1997). Docetaxel (Taxotere) in platinum-treated non-small cell lung cancer, a confirmation of prolonged survival in a multicenter trial. Proc Am Soc Clin Oncol, 16, 454a.
  9. Gillenwater HH, Tynan M, Natoli S, et al (2000). Second-line gemcitabine in refractory stage IV non-small-cell lung cancer, A phase II trial. Clin Lung Cancer, 2, 133-8. https://doi.org/10.3816/CLC.2000.n.026
  10. Gridelli C, Perrone F, Gallo C, et al (1999). Single-agent gemcitabine as second-line treatment in patients with advanced non small cell lung cancer (NSCLC), A phase II trial. Anticancer Res, 19, 4535-8.
  11. Hertel LW, Boder GB, Kroin JS, et al (1990). Evaluation of the antitumor activity of gemcitabine (20, 20-difluoro-20- deoxycytidine). Cancer Res, 50, 4417-22.
  12. Juergens R, Brahmer J, Ettinger D (2007). Gemcitabine and vinorelbine in recurrent advanced non-small cell lung cancer, sequence does matter. Cancer Chemother Pharmacol, 59, 621-9. https://doi.org/10.1007/s00280-006-0304-8
  13. Kosmas C, Tsavaris N, Syrigos K, et al (2007). A phase I-II study of bi-weekly gemcitabine and irinotecan as secondline chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens. Cancer Chemother Pharmacol, 59, 51-9.
  14. Lara PN Jr, Gumerlock PH, Mack PC, et al (2004). Gemcitabine in patients with nonsmall- cell lung cancer previously treated with platinum-based chemotherapy, A phase II California cancer consortium trial. Clin Lung Cancer, 6, 102-7. https://doi.org/10.3816/CLC.2004.n.023
  15. Le Chevalier T. (1995). Docetaxel, meeting the challenge of nonsmall cell lung cancer management. Anticancer Drugs, 6, 13-7. https://doi.org/10.1097/00001813-199507004-00003
  16. Lund B, Kristjansen PEG, Hansen HH (1993). Clinical and preclinical activity of 20,20-difluoro-20- difluorodeoxycytidine (gemcitabine). Cancer Treat Rev, 19, 45-55.
  17. Mattson K, Le Chevalier T, Stupp R, et al (1996). Preliminary report of Phase II study of docetaxel ($Taxotere^{(R)}$) in locally advanced or metastatic non-small cell lung cancer. Ann Oncol, 7, 429a.
  18. Robinet G, Kleisbaurer JP, Thomas P, et al (1996). Phase II study of Taxotere (docetaxel) in advanced or metastatic non-small cell lung cancer previously treated with platinum. Ann Oncol, 7, 96-7. https://doi.org/10.1093/annonc/7.suppl_3.96
  19. Robinet G, Kleisbaurer JP, Thomas P, et al (1997). Phase II study of docetaxel (Taxotere) in first and second-line NSCLC. Proc Am Soc Clin Oncol, 16, 480.
  20. Sculier JP, Lafitte JJ, Berghmans T, et al (2000). A phase II trial testing gemcitabine as second-line chemotherapy for non small cell lung cancer. The European Lung Cancer Working Party. Lung Cancer, 29, 67-73.
  21. Shepherd F, Dancey J, Ramlau R, et al (2000). Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol, 18, 2095-103. https://doi.org/10.1200/JCO.2000.18.10.2095
  22. Van Kooten M, Traine G, Cinat G, et al (1999). Single agent gemcitabine in pretreated patients with non-small-cell lung cancer, results of an Argentinean multicentre phase II trial. Br J Cancer, 81, 846-9. https://doi.org/10.1038/sj.bjc.6690774
  23. van Putten JW, Baas P, Codrington H (2001). Activity of singleagent gemcitabine as second-line treatment after previous chemotherapy or radiotherapy in advanced non-small-cell lung cancer. Lung Cancer, 33, 289-98. https://doi.org/10.1016/S0169-5002(01)00188-X
  24. Yokoyama A, Kurita Y, Watanabe K (1994). Early phase II clinical study of RP56976 (docetaxel) in patients with primary pulmonary cancer, docetaxel cooperative study group for lung cancer. Gan To Kagaku Ryoho, 21, 2609-16.

피인용 문헌

  1. Cationic Supramolecular Vesicular Aggregates for Pulmonary Tissue Selective Delivery in Anticancer Therapy vol.11, pp.16, 2016, https://doi.org/10.1002/cmdc.201600070